REGENERON PHARMACEUTICALS

Regeneron’s stock faces mixed signals amid cost‑control pressure; analysts keep ratings steady while the firm navigates pricing mandates and a growing PCSK9 market.

Regeneron’s exec LaRosa buys 45,000 shares, showing confidence yet sparking governance questions—insider moves reveal the biotech giant’s future and investor trust.

Regeneron shares dip after lawsuit, yet robust earnings on Dupixent, Eylea, and Libtayo keep growth momentum strong.

Regeneron Q2 2026: $4.3B revenue, Dupixent & EYLEA HD hit all‑time sales highs, $1.296B earnings, and a $0.94 dividend—strong growth, bullish outlook.

Regeneron’s Q2 2026 earnings preview promises to reveal whether the antibody‑therapeutics leader can keep its growth edge in a rapidly expanding market and stay ahead of rivals.

Regeneron is poised to dominate the growing $597 B antibody therapeutics market—leveraging a strong pipeline, solid trading metrics, and top‑5 biotech rankings to capture a major share by 2035.

Regeneron faces class‑action lawsuits, a failed Phase III trial, and a sharp stock drop, with investors eye upcoming earnings to gauge whether the biotech giant can recover.